Table 1.
Patient Characteristics
| Variable | Value |
|---|---|
| Age, yr | 68 (49–83) |
| Male sex | 14 (53.8) |
| Stage (UICC), IIa/IIb/III | 14/4/8 |
| Neoadjuvant therapy | |
| Chemotherapy | 17 (65.4) |
| Chemoradiation therapy | 9 (34.6) |
| Chemotherapy regimen | |
| Gemcitabine plus nab-paclitaxel | 5 (19.2) |
| FOLFIRINOX | 1 (3.8) |
| Gemcitabine plus S-1 | 3 (11.5) |
| Gemcitabine | 5 (19.2) |
| S-1 | 6 (23.1) |
| Others | 6 (23.1) |
| Initial total bilirubin, mg/dL | 6.8 (0.4–23.0) |
| Preoperative CA 19-9, U/mL | 341.3 (1–10,618) |
| Preoperative biliary drainage period, mo | 4.0 (2.1–33.8) |
Data are presented as median (range) or number (%).
UICC, International Union Against Cancer; FOLFIRINOX, irinotecan, oxaliplatin, leucovorin, and fluorouracil (5-FU); CA 19-9, carbohydrate antigen 19-9.